ZYME vs RXRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZYME · Zymeworks$29.63 ▲ 3.11%
RXRX · Recursion Pharmaceuticals$3.52 ▲ 0.57%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZYME +64.2%
- RXRX -22.0%
Head to head
| Metric | ZYME | RXRX |
|---|---|---|
| Price | $29.63 | $3.52 |
| Change today | ▲ 3.11% | ▲ 0.57% |
| Market cap | $2.09B | $2.19B |
| Return, 3 months | +22.6% | +7.0% |
| Return, year to date | +12.5% | -13.9% |
| Return, 1 year | +80.0% | -23.8% |
| P/E (TTM) | – | – |
| P/B | 26.0 | 2.4 |
| P/E percentile vs own 5y | 21st | 60th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -90.6% | -61.8% |
| Net profit growth (YoY) | -2,043.0% | +23.8% |
| Gross margin | – | 1.8% |
| Operating margin | -419.0% | -1,008.5% |
| Net margin | -404.0% | -962.0% |
| Return on equity | -72.3% | -56.6% |
| Analyst target vs. price | +38.9% | +88.4% |
| Analyst buy share | 100% | 40% |
| RSI (14) | 59 | 44 |
| 30-day volatility | 47.2% | 111.1% |
| Max drawdown, 1 year | -23.6% | -54.9% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RXRX is the largest of the group by market value.
- ZYME has returned the most over the past year.
- RXRX is growing revenue fastest.
- ZYME keeps the most profit per dollar of sales.
- ZYME has been the calmest stock over the last 30 days.